Jasper Therapeutics
PublicJasper Therapeutics is now publicly traded
The data on this page reflects Jasper Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
PIPE
Aug 5, 2026
Total Funding Raised
$132M
Company Overview
Jasper Therapeutics is a biotechnology company that develops monoclonal antibody therapies for chronic mast cell-driven diseases and hematopoietic stem cell transplantation.
Sector
Biotech
AI Layer
Non-AI
Keywords
Jasper Therapeutics Comparables
Compare Jasper Therapeutics with similar companies based on industry and business-model similarity.
No public comparables are available for Jasper Therapeutics. Request access to learn about comparables coverage.
Request accessJasper Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Aug 5, 2026 |
Key People
Founding team and executive leadership
Jasper Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Balyasny Asset Management L.P. | PIPE |
| Columbia Threadneedle Investments | PIPE |
| Ikarian Capital | PIPE |
| Brahma Capital | PIPE |
| SilverArc Capital Management | PIPE |
| Nazare Partners | PIPE |
| Affinity Asset Advisors | PIPE |
Recent news
Latest coverage and updates
- merges_withJul 20, 2026
Jasper Therapeutics, Inc. merged with Kira Pharma Company on Jul 23rd '26.
Jasper Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access